Coverage

  • mRNA Looks Beyond COVID-19 Vaccines to Therapeutics and Diagnostics August 19th, 2021

    Leveraging mRNA to develop game-changing medicines has already been demonstrated with the development of vaccines to tackle the COVID-19 pandemic. In this articleBioSpace goes beyond the currently available vaccines to discuss the potential mRNA-based therapeutics hold in fostering the next wave of therapeutics for many diseases or conditions that cannot be treated otherwise.

  • Create Value & Success Will Follow, Anima Biotech CEO Yochi Slonim Says July 23rd, 2021

    In this story, Anima Biotech Co-Founder and CEO, Yochi Slonim, shares his philosophies about what it takes to be an optimal collaborator in the life sciences industry. From his beginnings as a serial entrepreneur in the world of high tech, Mr. Slonim shared how his professional path led him to co-found Anima and how the company is focused both on expanding its internal pipeline while simultaneously identifying large pharma/biotech companies that share the same vision as Anima in developing potentially game-changing small molecule drugs for a variety of hard-to-treat diseases.

  • The Bio Report - Modulating the Translation of Proteins July 8th, 2021

    The development of mRNA therapies is allowing drug developer to pursue targets once considered undruggable. Anima Biotech has developed a platform that allows it to use small molecule that selectively control mRNA and can decrease or increase the translation of proteins. The approach has broad applicability as evidenced by the company’s pipeline, which includes experimental therapies for oncology, neurology, infectious disease, and fibrosis. We spoke to Yochi Slonim, CEO of Anima, about the company platform technology, how it can modulate the expression of proteins, and how it is leveraging its technology through partnerships with some of the world’s largest pharmaceutical companies.

  • Anima Biotech Heads for the Light with Up-to-$2.4B Takeda Partnership March 22nd, 2021

    In this article, Anima Biotech Co-Founder and CEO, Yochi Slonim, discusses the journey to their up-to $2.4 billion collaboration with Takeda Pharmaceuticals to develop small molecule mRNA translation modulators in Neuroscience. From his background as a serial entrepreneur to the development of Anima’s proprietary Translation Control Therapeutics Platform, the article provides context for the success of the company’s mRNA-focused drug discovery pipeline.

  • Takeda bags mRNA translation modulators in $120M Anima deal March 19th, 2021

    The maximum size of the Anima deal could swell to more than $2 billion. (Takeda)
    Takeda has teamed up with Anima Biotech to discover mRNA translation modulators. The Japanese drugmaker is set to pay up to $120 million in upfront fees and preclinical research milestones to work with Anima on the treatments for genetically defined neurological diseases.

  • Anima signs new strategic collaboration deal with Takeda March 19th, 2021

    Anima Biotech has announced its new strategic collaboration deal with Takeda Pharmaceutical Company for the discovery and development of new medicines to combat genetically defined neurological diseases.

  • Anima and Takeda to develop mRNA modulators for neurological diseases March 19th, 2021

    Anima Biotech and Takeda Pharmaceutical are collaborating to discover and develop mRNA translation modulators for neurological diseases. According to the deal, Anima will discover mRNA translation modulators using its Translation Control Therapeutics platform to develop a new class of medicines for genetically-defined neurological diseases.

  • Takeda spreads it bets in Huntington’s March 18th, 2021

    Takeda already has one shot in Huntington’s, via a 2018 deal with Wave Life Sciences. The Japanese company put down another marker in the disease today by teaming up with the private Israeli company Anima Biotech.

  • Anima and Takeda to Collaborate on Neurological Disease Therapeutics March 18th, 2021

    Anima Biotech, a company focused on the discovery of small molecule drugs that selectively control mRNA translation, has entered into a strategic collaboration with Takeda Pharmaceutical to discover and develop a new class of medicines for genetically defined neurological diseases.

  • Anima attracts Takeda in potential multibillion-dollar deal March 18th, 2021

    Small-molecule mRNA translation expert Anima Biotech Inc. has landed a significant new preclinical research deal with Takeda Pharmaceutical Co. Ltd., covering as many as six programs for genetically-defined neurological diseases. The deal starts with $120 million for Anima up front, but altogether, the two-part collaboration could hold as much as $2.3 billion in clinical and commercial milestone payouts for the company, providing substantial support for its internal pipeline, Anima’s co-founder and CEO Yochi Slonim told BioWorld.

  • Living in its post-Shire world, Takeda continues aggressive licensing push in $2.3B deal with Anima March 18th, 2021

    Takeda has signed a collaboration with Anima Biotech, covering up to six different programs with promises of up to $2.3 billion in milestones. Under the deal, Anima will initially conduct preclinical research for Huntington’s disease, as well as two other small molecule candidates.

  • Anima Biotech and Takeda Enter Collab to Target mRNA Translation with Small Molecules March 18th, 2021

    Anima Biotech’s strategic collaboration with Takeda Pharmaceutical, just announced today, uses its novel platform for discovery of mRNA translation modulators to discover and develop a new class of therapies for neurological diseases.

  • Anima Biotech, Takeda Collaborate To Develop MRNA Translation Modulators For Neurological Diseases March 18th, 2021

    Anima Biotech said that it reached a strategic collaboration with Takeda Pharmaceutical Company Limited to discover and develop a new class of medicines for genetically-defined neurological diseases.

    As per the terms of the deal, Anima will use its Translation Control Therapeutics platform to discover novel mRNA translation modulators against the collaboration targets.

  • Anima Biotech’s mRNA Technology is Lighting Up Novel Drug Targets February 12th, 2021

    In this Q&A interview with our CEO, Yochi Slonim, senior editor Andrew Matthius of PM360 highlights how Anima’s approach of discovering small molecules that can selectively control mRNA translation to treat diseases is shifting the paradigm in how we think about drug discovery and development. In this piece, Mr. Slonim shares the beginnings of Anima, the current state of mRNA drug development given the COVID-19 pandemic and how Anima’s approach is unique in that they are not discovering small molecules to bind to mRNA, but rather targeting the translation of these proteins.  

  • Biopharma Executive Perspectives on 2021 January 11th, 2021

    In this review with fellow top executives from the biotechnology space, our CEO Yochi Slonim speaks about what the industry has learned from this past year and his predictions for 2021. Mr. Slonim describes the biggest new source of drugs and Anima's approach to open up this goldmine of novel targets by finding small molecules that can bind to the proteins that regulate protein translation rather than drugging mRNA or proteins directly.

  • Expanding small-molecule target space to mRNA translation regulation December 16th, 2020

    In the open access Elsevier journal, Drug Discovery Today, experts from Anima highlight mRNA translation regulatory mechanisms and potential drug-intervention targets. Underlying Anima’s approach is a new scientific rationale of translation regulation, which consequently has led to this new target space. In this article, the authors take a deep dive into how Anima’s unique discovery platform is able to identify selective small molecule drugs that affect translation of specific proteins, which has enabled targeting of proteins that may have been previously deemed, undruggable.

  • Targeting “Undruggable” Proteins by Selectively Controlling mRNA Translation August 17th, 2020

    In this interview with senior science writer and editor, Laura Lansdowne of Technology Networks, our co-founder and CEO Yochi Slonim discusses Anima Biotech’s background, technology platform, and our strategy against previously deemed ‘undruggable’ targets to help underserved patients with hard-to-treat diseases.

  • Seeing the light – visualising protein translation in real time June 7th, 2020

    In this article by Nikki Withers, our CEO Yochi Slonim discusses how Anima’s drug discovery platform, Translation Control Therapeutics, can track the exact location and rate of protein synthesis for any target protein of interest involved in a disease leveraging FRET light pulses to visualize mRNA translation from within ribosomes. This approach enables the discovery of small molecules that modulate the translation of a target protein as an entirely novel target space to aid in the treatment of undruggable diseases

  • Anima biotech named Startup City’s 15 Most Promising Biotech Startups of 2019 November 4th, 2019

    Anima biotech was named Startup City’s 15 Most Promising Biotech Startups of 2019. In the feature, our CEO Yochi Slonim discusses how Anima’s drug discovery platform, Translation Control Therapeutics, can track the exact location and rate of protein synthesis for any target protein of interest involved in a disease. This piece also examines the current mRNA therapeutics space.

  • Update on platform & Lilly partnership October 27th, 2019

    Anima Biotech Inc CEO Yochi Slonim caught up with Proactive at the 2019 BIO Investor Forum in San Francisco. 

    Slonim updated investors on its Translation Control Therapeutics platform and reflected on the company's partnership with Eli Lilly and Company.

  • Proteins May Be Nipped (or Nurtured) in the Translational Bud September 4th, 2019

    In this interview with Gail Dutton in Genetic Engineering & Biotechnology News, our CEO Yochi Slonim discusses Anima Biotech’s novel strategy and approach to the discovery and development of new small molecule drugs that target and control the process of mRNA translation into proteins.

  • No Longer Lost in Translation September 3rd, 2019

    In this deeper dive into how biopharmaceutical companies are approaching translational medicine, our CEO Yochi Slonim and other experts in the industry discuss novel targets in drug discovery and how to increase the number of drugs that can be successfully brought to market.

  • Seeking Small Molecule Drugs to Control mRNA Translation August 28th, 2019

    In this article by Chelsea Weidman Burke, our CEO Yochi Slonim discusses how Anima’s own drug discovery platform, Translation Control Therapeutics, can track the exact location and rate of protein synthesis for any target protein of interest involved in a disease. This piece also examines the current mRNA therapeutics space.

  • Better, safer, small molecule drugs July 17th, 2019

    This piece written by Cath O’Driscoll discusses Anima’s new approach to the discovery of small molecule drugs to target previously hard to treat diseases and could lead to safer, more versatile treatments.

  • Anima Biotech featured in BioWorld June 13th, 2019

    Coverage from a panel during the 2019 BIO convention features the leaders and founders of emerging platform companies including our own CEO Yochi Slonim. This article reviews what makes platform players different from other biopharma ventures and how Anima Biotech’s own drug discovery platform works to identify new small molecules that affect protein synthesis.

  • Bringing Small Molecule Discovery to mRNA Space May 30th, 2019

    This video interview with Mike Ward (Pharma Intelligence) at BIO-Europe Spring 2019, showcases Anima Biotech’s novel approach to discover small molecule drugs that regulate and control the process of mRNA translation into proteins. 

  • Anima Biotech featured in the 2019 Quarter 2 issue of Pharma’s Almanac May 28th, 2019

    In this roundtable review, our CEO Yochi Slonim answers the question “What truly novel therapies in the earliest stages of discovery and development do you believe will have a significant impact in the future?” Mr. Slonim describes more traditional approaches to drug discovery and how Anima is opening up an entirely different space of novel targets by finding small molecules that can bind to the proteins that regulate protein translation rather than drugging mRNA or proteins directly.

  • Anima opens new target space in Translational Control May 24th, 2019

    This feature by Lauren Martz, Associate Editor of BioCentury, covers how Anima Biotech is leveraging its Translation Control Therapeutics platform to purse novel targets of mRNA translation regulators in order to develop tissue selective small molecule drugs.

  • mRNA and Artificial Intelligence: An Interview with Anima Biotech’s Yochi Slonim May 23rd, 2019

    In this interview with our CEO Yochi Slonim, Mark Terry, contributing writer to BioSpace, examines Anima Biotech’s unique approach to mRNA therapeutics and its high throughput screening technology platform to identify small molecules that can decrease or increase mRNA translation into proteins.

  • Anima Biotech - mRNA translation control December 13th, 2018

    In this video, learn how Anima Biotech’s platform can visualize the protein synthesis process allowing scientists to gain insights into the mechanisms of disease and discover new drugs that control protein translation.

  • Eli Lilly & AnimaBiotech win US Deal of the Year Award November 15th, 2018

    In this video interview with Tim Luker, Senior Director, Emerging Technology & Innovation at Eli Lilly & Co., describes what the collaboration with Anima Biotech and the potential of Anima’s Translation Control Therapeutics technology means to the future of drug discovery at Eli Lilly.

  • Anima Biotech Lighting The Way In Protein Translation August 1st, 2018

    This company profile, written by Jo Shorthouse, establishes Anima Biotech as a leader in the translation biology space with its technology for the discovery and development of small molecule drugs that control and regulate protein synthesis.

  • Lilly links with Anima July 24th, 2018

    Eli Lilly is teaming up with Anima Biotech in collaboration to discover and develop translation inhibitors for several protein targets.

  • Eli Lilly Signs Multi-Year Collaboration with Anima Biotech July 23rd, 2018

    Israel-based Anima will receive an upfront payment of $30 million and $14 million for research, but could potentially get as much as $1.05 billion in milestones

  • Lilly inks R&D deal with Anima, paying $44M in research funding and upfront payments July 23rd, 2018

    Eli Lilly $LLY is commissioning a small team in New Jersey to implement its unusual approach to drug discovery on a few of Lilly’s targets, paying out $30 million in an upfront fee plus some cash to get the research started.

  • Anima Biotech Inks $1 Billion-Plus Deal with Eli Lilly July 23rd, 2018

    Anima Biotech, based in Bernardsville, New Jersey, inked a discovery and development deal with Eli Lilly and Co. that has the potential to exceed $1 billion.

  • Anima, Eli Lilly pen $1B-plus biobucks research pact July 23rd, 2018

    Anima Biotech has signed a deal with Eli Lilly potentially worth more than $1 billion in biobucks as the pair seeks to work on the biotech’s translation inhibitors.

  • This Israeli Biotech Targets Protein Translation to Fight Disease April 13th, 2018

    In a company examination, this article describes the therapeutic potential of Anima Biotech’s Translation Control Therapeutics technology in the discovery of small molecules that control protein translation.